Common Prescription Drugs Linked to Higher C. difficile Infection Risk: Swedish Study

Which Common Drugs Increase Clostridioides difficile Risk Beyond Antibiotics?

Clostridioides difficile infection (CDI) is widely recognized as a consequence of antibiotic use, which disrupts the normal gut microbiome and allows the pathogen to flourish. However, a new population-based case–control study from Sweden, published in Gut, demonstrates that the risk landscape extends well beyond antibiotics alone. The research examined prescription records across a large Swedish population to identify which commonly used medications independently raise CDI risk.

Proton pump inhibitors (PPIs), among the most widely prescribed drugs globally for acid reflux and ulcers, emerged as a notable risk factor. PPIs reduce stomach acid, which normally serves as a barrier against ingested pathogens including C. difficile spores. Previous studies have suggested this association, and the Swedish data adds robust population-level evidence. The study's case–control design, drawing on comprehensive national health registries, strengthens the reliability of these findings compared to smaller or single-center analyses.

Why Does This Matter for Patients and Prescribers?

C. difficile infection remains one of the most significant healthcare-associated infections worldwide. The US Centers for Disease Control and Prevention (CDC) has classified C. difficile as an urgent threat, with approximately 500,000 infections and tens of thousands of deaths estimated annually in the United States alone. Identifying modifiable risk factors beyond antibiotics is therefore a public health priority. If commonly prescribed drugs contribute meaningfully to CDI incidence, targeted deprescribing or closer monitoring could reduce the burden of disease.

The findings carry particular weight given the scale of PPI use globally. Estimates suggest that PPIs are among the top ten most prescribed drug classes in many countries, and concerns about overprescription and long-term use have already been raised by gastroenterology societies. This study adds C. difficile risk to the growing list of reasons clinicians should periodically reassess the need for ongoing PPI therapy, especially in older adults and hospitalized patients who are already at elevated CDI risk. The researchers emphasize that their findings do not mean these drugs should be avoided entirely, but rather that prescribers should weigh CDI risk alongside other known adverse effects when making treatment decisions.

How Was the Swedish Study Conducted?

Sweden's comprehensive national health registries, which capture virtually all prescription dispensations and hospital diagnoses, provided an ideal setting for this research. The case–control design compared individuals diagnosed with CDI against matched controls from the general population, examining prescription drug use in the period preceding infection. By adjusting for antibiotic exposure and other confounders, the researchers were able to isolate the independent contribution of non-antibiotic drugs to CDI risk.

This methodological approach overcomes many limitations of earlier studies, which often relied on hospital-only populations or lacked the statistical power to separate the effects of multiple concurrent medications. The population-based design also means the results are more generalizable to everyday clinical practice rather than being limited to high-risk hospital settings. The study adds to a growing body of evidence calling for a broader understanding of CDI risk factors and more nuanced antimicrobial stewardship programs that also consider the role of non-antibiotic prescriptions.